Project Grant R21AI190212
Award Date
4/8/25
Completion Date
3/31/27
Dollars Obligated
$193K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Mobile, AL 36688, USA
Similar Awards
This $222,109 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund a research project to investigate the impacts of the Borrelia burgdorferi GAC protein on infectivity and regulation of virulence protein expression in the Lyme disease spirochete. The key objectives of the study are to further characterize the functions of GAC, including its effects on mammalian and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $382,500.00 to Washington State University (WSU) to conduct fundamental research on the role of genetic factors encoded on the LP17 plasmid of the Lyme disease spirochete, Borrelia burgdorferi. The key objectives are to: 1) Establish the importance of the BBD21 and BBD22 genes for controlling the copy number of B....
The federal Project Grant award R01AI181738, totaling $509,130.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research to define the global virulence regulatory network in the Lyme disease pathogen Borrelia burgdorferi (BB). The research aims to: 1) Determine the BB BosR regulon and characterize the contributions of BosR-regulated genes to BB's infectious cycle;...
The Virginia Commonwealth University was awarded a $746,009 Project Grant from the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases. The grant falls under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research examining the cyclic-di-GMP signaling pathway and its role in the enzootic cycle of Lyme disease from November 18, 2022 through October 31, 2027. Specifically, the grant will fund...
This $3,019,293 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund a 5-year prospective study on persistent symptoms of Lyme disease. The primary objectives are to: Coordinate the collection, processing, and diagnostic testing of human samples from enrolled Lyme disease patients through the Diagnostics Core at Massachusetts General Hospital. This will include developing a biorepository of...
This $199,984 Project Grant awarded by the National Science Foundation (NSF) Engineering program (CFDA 47.041) aims to increase the fundamental understanding of the immune response to various Lyme disease antigens using bacterial outer membrane vesicles (OMVs) as a novel carrier system. The research objectives are to: 1) explore fusion proteins as a proof of concept to present full Borrelia burgdorferi (BB) antigens on OMVs, 2) determine the potential to express multiple BB antigen epitopes on...
The University of Montana was awarded a $1,342,868 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the role of the FBB-1 phage in Borrelia burgdorferi, the bacterium that causes Lyme disease. The key objectives of the 5-year project are to: 1) Measure horizontal gene transfer between Borrelia burgdorferi strains in ticks, 2) Define the role of the FBB-1 phage in...
The federal Project Grant award R21AI182112 for $191,250.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award aims to investigate the mechanistic details of antigenic variation in the Lyme disease spirochete Borrelia burgdorferi, specifically focused on elucidating the role of genetic factors in the VlsE surface protein variation. The research seeks to establish the importance of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,933 to L2 Diagnostics LLC to develop a novel therapeutic for Lyme arthritis based on a secretory leukocyte protease inhibitor (SLPI). The goal is to demonstrate the feasibility of using SLPI to mitigate Lyme arthritis in a murine model, with the long-term objective of creating a SLPI-based therapeutic for advanced...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $187,734 to Michigan State University (MSU) to develop a mouse model for studying Lyme neuroborreliosis (LNB). The project aims to identify mouse strains that are susceptible to neurological infection by Borrelia burgdorferi, the bacteria that cause Lyme disease. Specifically, the research will: Determine if the...